Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

02.11.2017 | review article | Ausgabe 3-4/2018 Open Access

Wiener klinische Wochenschrift 3-4/2018

Review of cancer treatment with immune checkpoint inhibitors

Current concepts, expectations, limitations and pitfalls

Wiener klinische Wochenschrift > Ausgabe 3-4/2018
MBA, MSc Priv. Doz. Dr. Christiane Thallinger, Thorsten Füreder, Matthias Preusser, Gerwin Heller, Leonhard Müllauer, Christoph Höller, Helmut Prosch, Natalija Frank, Rafal Swierzewski, Walter Berger, Ulrich Jäger, Christoph Zielinski


Immunotherapy by checkpoint inhibition is about to profoundly change cancer therapy. The number of indications are growing at an unprecedented speed. Clinical studies have demonstrated efficacy in a variety of solid tumors and in hematologic malignancies, although some clinical trials have produced negative results. Thus, it is fair to assume that there are obvious limitations and pitfalls in immunotherapy. Future concepts for combination treatment of immune checkpoint inhibitors have to be developed, but there is also urgent need for better and standardized biomarkers to identify those cancer patients who will benefit from treatment by checkpoint inhibition. The current overview summarizes current knowledge on immune checkpoint inhibitor treatment in malignancies, its outlook and limitations, diagnostic means and, finally, side effect management.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 3-4/2018

Wiener klinische Wochenschrift 3-4/2018 Zur Ausgabe